ADVERTISEMENT
  • News
  • New York
  • Technology
  • Culture
  • Entertainment
  • Sport
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Sunday, April 6, 2025
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Business Pharmacy

Patients Taking Cymbalta Experienced Reduced Chronic Low Back Pain in New Study

The FINANCIAL by The FINANCIAL
August 25, 2008
in Pharmacy
Reading Time: 3 mins read
8
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — According to Lilly, data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.

 

Results from the double-blind, 13-week, placebo-controlled study of 236 patients were presented today at the annual congress of the European Federation of Neurological Societies (EFNS) in Madrid, Spain.

RelatedPosts

A Closer Look at Bioactive Peptides and Their Impact on Health

Roche ranked the most sustainable healthcare company in the DJSI

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

 

Duloxetine-treated patients reported significantly greater reduction in pain scores than placebo-treated patients. Thirty-one percent of duloxetine-treated patients experienced a 50 percent reduction in pain, compared with 19 percent of placebo-treated patients, as measured by an 11-point Likert pain scale. Physicians consider a pain reduction of at least 30 percent as clinically significant.

 

Treatment with duloxetine also was associated with improved patient outcomes as measured by the Patient Global Impressions of Improvement (PGI-I), and physical functioning as measured by the Roland Morris Disability Questionnaire (RMDQ-24).

 

Significantly more patients in the duloxetine group discontinued because of adverse events. In this study, the most common adverse events (those occurring in more than 5 percent of patients in the duloxetine group) were nausea, dry mouth, fatigue, diarrhea, excessive sweating (hyperhidrosis), dizziness and constipation. Adverse events were similar to those seen in previous duloxetine studies in other disease states.

 

"Chronic low back pain can have a significant impact on a person's ability to do the things they enjoy," said Vladimir Skljarevski, lead study author and a neurologist and medical fellow at Lilly Research Laboratories. "This research may offer hope to those dealing with this debilitating condition."

 

Study Methods

 

Adult patients given duloxetine (n=115) and those given placebo (n=121) with a history of non-neuropathic chronic low back pain for more than six months with a weekly mean 24-hour average pain score greater than or equal to 4 at baseline (0-10 scale) and without major depressive disorder were initially treated with duloxetine 60 mg once daily for the first seven weeks in this randomized placebo-controlled trial. After seven weeks of duloxetine treatment, patients reporting less than 30 percent pain reduction (non-responders) had their dose increased to 120 mg once daily. Responders continued on 60 mg once daily. The study's primary objective was the reduction of the BPI 24-hour average pain score. Secondary measures included RMDQ-24, PGI-I, BPI Severity portion (BPI-S) and BPI Interference portion (BPI-I), diary-based weekly mean of the 24-hour average pain score, Clinical Global Impression of Severity (CGI-S), and response rates. Health outcomes, safety and tolerability also were assessed. Continuous efficacy variables were analyzed using analysis-of-variance (ANOVA) with treatment and investigator in the model, or analysis of covariance, with baseline, treatment and investigator in the model, and the stratifying variable of NSAID use (Yes/No). Mixed-model repeated measures (MMRM) analysis also was used to measure improvement at all time points. Treatment groups were compared based on the difference between least-squares means using two-sided testing at the 0.05 significance level. Safety analyses were conducted to compare treatment groups using Fisher's exact test.

 

Duloxetine data also presented at 12th World Congress of Pain

 

Data from a separate duloxetine chronic low back pain study were presented on Aug. 21 at the 12th World Congress of Pain in Glasgow, Scotland. At study endpoint, duloxetine did not significantly differ from placebo on the primary measure of weekly mean 24-hour average pain score. However, patients taking duloxetine 60 mg once daily showed significant pain reductions compared with placebo from week three through week 11 of the 13-week trial. This was the first study designed to assess the effect of duloxetine on the reduction of chronic low back pain compared with placebo.

 

In the 13-week, double-blind, randomized, placebo-controlled study (n=404), patients taking duloxetine 60 mg once daily experienced statistically significant improvements in several secondary outcome measures compared with placebo. Patients taking duloxetine 60 mg once daily also experienced a statistically significant improvement in patient outcomes as measured by the PGI-I and physical functioning as measured by the RMDQ-24. In this study, the most common adverse events (those occurring in more than 5 percent of patients in the duloxetine group) were nausea, insomnia, dry mouth, constipation, headache, diarrhea, dizziness, somnolence (drowsiness) and fatigue.

 

It is estimated that at least 15 million adults in the United States have chronic low back pain.According to the International Association for the Study of Pain (IASP), pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Chronic pain is defined as pain that persists beyond acute pain or beyond the expected time for an injury to heal.(6) Men and women are equally affected by chronic low back pain, and it occurs most often between ages 30 and 50.

 

 

Related Posts

A Closer Look at Bioactive Peptides and Their Impact on Health
Clinics

A Closer Look at Bioactive Peptides and Their Impact on Health

by Accessily
October 15, 2024
0

Introduction to Bioactive Peptides What are Bioactive Peptides? Bioactive peptides are short protein fragments, typically ranging from 2 to 20...

Read more
Roche ranked the most sustainable healthcare company in the DJSI

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020
Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

November 16, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 12, 2020

Discussion about this post

  • Trending
  • Comments
  • Latest
Bvlgari, Ferrari & Louis Vuitton: 3 Exceptional New Partners for the International Master in Luxury Management

Bvlgari, Ferrari & Louis Vuitton: 3 Exceptional New Partners for the International Master in Luxury Management

March 31, 2025
Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

April 1, 2025
Fort Lauderdale’s Coolest Spots: A Guide to the City’s Must-Visit Destinations

Fort Lauderdale’s Coolest Spots: A Guide to the City’s Must-Visit Destinations

March 30, 2025
Ampersand wins £22m five-year contract at London Zoo

Ampersand wins £22m five-year contract at London Zoo

June 25, 2012
New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

April 3, 2025
European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

April 6, 2025
Loans

Protected: What Are the Factors That Affect Housing Loan Interest Rates?

April 5, 2025
How Do Bullet-Resistant Windows Improve Safety?

How Do Bullet-Resistant Windows Improve Safety?

April 3, 2025
New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

April 3, 2025
How to Deep Clean Your Air Fryer in 5 Easy Steps

How to Deep Clean Your Air Fryer in 5 Easy Steps

April 3, 2025
ADVERTISEMENT

Popular Last 24h

  • Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

    Eshvi Signals The Beginning of a Bold New Era by Opening A New Location

    107 shares
    Share 43 Tweet 27
  • European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

    18 shares
    Share 7 Tweet 5
  • Ampersand wins £22m five-year contract at London Zoo

    3006 shares
    Share 1202 Tweet 752
  • What Are the Income Limits for Deducting Traditional IRA Contributions in 2025?

    38 shares
    Share 15 Tweet 10
  • Boost Your Online Presence:

    28 shares
    Share 11 Tweet 7
  • New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

    39 shares
    Share 16 Tweet 10
  • How Do Bullet-Resistant Windows Improve Safety?

    21 shares
    Share 8 Tweet 5

LATEST POSTS

European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

European Experts on safeguarding cultural heritage from extreme risks are invited to participate in the READY Project

April 6, 2025
Loans

Protected: What Are the Factors That Affect Housing Loan Interest Rates?

April 5, 2025
How Do Bullet-Resistant Windows Improve Safety?

How Do Bullet-Resistant Windows Improve Safety?

April 3, 2025
New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

New US Tariffs Hit the US Itself Hardest: Medium- to Long-Term Impacts

April 3, 2025
How to Deep Clean Your Air Fryer in 5 Easy Steps

How to Deep Clean Your Air Fryer in 5 Easy Steps

April 3, 2025
Muslim Pro App CEO Addresses Data Privacy Concerns and Outlines Enhanced Security Measures

Muslim Pro App CEO Addresses Data Privacy Concerns and Outlines Enhanced Security Measures

April 3, 2025
Between 1979 and 2022, the total register has increased by 4.1 million companies

Tariff-ic government?

April 3, 2025
retirement-mza.jpg

What Are the Income Limits for Deducting Traditional IRA Contributions in 2025?

April 3, 2025
Energy bills are the area of spending most concerning Britons

Energy bills are the area of spending most concerning Britons

April 1, 2025
Homelessness Crisis in New York: The Intersection with Illegal Immigration

Homelessness Crisis in New York: The Intersection with Illegal Immigration

April 1, 2025

LATESTINTERVIEWS

Interview: Former British Air Commander Says Ukraine Must ‘Inflict Maximum Pain’ On Russia

Interview: Former British Air Commander Says Ukraine Must ‘Inflict Maximum Pain’ On Russia

by The FINANCIAL
September 17, 2024
0

Bizzy Cold Brew CEO Reveals What’s Fueling Ambitiously Strong Brand

Bizzy Cold Brew CEO Reveals What’s Fueling Ambitiously Strong Brand

by Merilee Kern, MBA

Washington Wants to Avoid a Repeat of Last Year’s NATO Summit

Washington Wants to Avoid a Repeat of Last Year’s NATO Summit

by The FINANCIAL
June 28, 2024
0

Tamar Ghlonti, the Acting Director of Radio Maestro

Radio Maestro: Promoting Business Growth and Development in Georgia

by Golden Brand
June 15, 2024
0

Lika Lobzhanidze, founder and director of ArtPharma

Vitaferol – Top Vitamin D brand in Georgia

by Golden Brand
June 15, 2024
0

Tea Meskhi, the Marketing Manager of the Turkish pharmaceutical company Asfarma

Customer Satisfaction, Trust Lead Aksen Fort to Win Golden Brand in Georgia

by Golden Brand
June 15, 2024
0

Aleksandre Metreveli - Director of the company

Ekokemika Service Group to Unveil New Line of Household Chemicals This Year

by Golden Brand
June 15, 2024
0

Lasha Babuadze, The-founder of Iberia Product

Anchor Butter Georgian Customers’ Favorite for The Fifth Time at Golden Brand Awards

by Golden Brand
June 15, 2024
0

GET IN TOUCH

Submit guest post/Letters to the Editor:

editor (at) finchannel.com

Sales & Marketing: (+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Whatsup: +995599965252

USA:

+1 917-795-8866

Georgia:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2025 Intelligence Group llc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

- Select Visibility -

    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.